As GEN, we announced the positive results of the Phase 2 clinical…
GEN Won the Bronze Award from the 2024 Brandon Hall Group HCM…
GEN Once Again on the Fortune 500 Türkiye List! We are ranked…
GEN has signed an important partnership and collaboration agreement with Jaguar Health.…
GEN initiates Phase 1 study of the first-in-class investigational drug SUL-238 Ankara,…
As one of Türkiye's fastest-growing pharmaceutical companies, we are pleased to be…
GEN 2022 Sustainability Report has been published in accordance with GRI standards.…
We are pleased to announce that we have signed a new agreement…
Our company Gen İlaç ve Sağlık Ürünleri San. ve Tic. A.Ş. (GEN)…
We are delighted to announce that as GEN, we have become a…
GEN was deemed worthy of the ETİKA award by being one of…
As one of Turkey's fastest growing pharmaceutical companies, we are happy to…
We have signed a Local Representative and Services Agreement with MODERNA. Under…
As a result of the search for new products, new production-sales-distribution relations/regions,…
GEN has received European Union Good Manufacturing Practices (EU GMP) approval, which…
GEN is investing in a biotechnology start-up RS Research, developing novel drugs for cancer patients
GEN İlaç ve Sağlık Ürünleri Sanayi ve Ticaret A.Ş. (GEN), a leading…
We are included in the Turquality program, the first-ever state-funded branding program…
SULFATEQ and GEN sign definitive collaboration agreement to develop a therapy for…
We are proud to announce that we have taken yet another important…
As GEN, we continue to deliver our Rare Solutions around the globe.…
We got our Great Place To Work certificate. We value human life…
We are greatly pleased and honored to receive a visit to our…
ZUG, Switzerland & ANKARA, Turkey--(BUSINESS WIRE)--Mar. 25, 2020-- Alnylam Pharmaceuticals, Inc. (Nasdaq:…
Another milestone for GEN in its mission to give the best service…
